

# Compare the combination of traditional Chinese medicine (Qingre Huashi Quyu) and mesalazine with mesalazine for the treatment of ulcerative colitis.

<b>Submission date</b> 25/04/2019	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 07/05/2019	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 29/10/2021	<b>Condition category</b> Digestive System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Ulcerative colitis (UC) is a non-specific inflammation of the intestine, with abdominal pain, diarrhea, mucus pus and bloody stools and urgency as the main clinical manifestations. Because the cause is unknown, difficult to cure, easy to progress to a cancer, it has been listed as a difficult disease by the World Health Organization (WHO). This study aims to determine whether the Qingrehuashiquyu recipe might help those UC patients, as previous studies have shown it may be beneficial.

### Who can participate?

Adults aged 18-65 who have been diagnosed by their doctors as having ulcerative colitis.

### What does the study involve?

Participants are randomly allocated to one of two groups:

1. Qingrehuashiquyu recipe 200ml, taken orally two times per day and mesalazine 0.25g, taken orally four times per day for 12 weeks
2. Mesalazine 0.25g taken orally four times per day for 12 weeks

Following completion of this 8 week period, there is another 12 week follow-up period.

### What are the possible benefits and risks of participating?

The possible benefit of participating is that the Qingrehuashiquyu recipe and mesalazine may improve symptoms of patients, although this cannot be guaranteed. The possible risks of participating are that the treatment may cause side effects including epigastric discomfort, nausea, headache and dizziness, although this is unlikely.

### Where is the study run from?

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, China

When is the study starting and how long is it expected to run for?  
June 2018 to August 2022

Who is funding the study?  
Beijing municipal commission of science and technology

Who is the main contact?  
Dr Luqing Zhao  
zhaoluqing111@163.com

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Luqing Zhao

**ORCID ID**  
<https://orcid.org/0000-0003-1986-3511>

**Contact details**  
No. 23  
Art Museum Houjie Street  
Dongcheng District  
Beijing  
China  
100010  
+8601052176634  
zhaoluqing111@163.com

## Additional identifiers

**Clinical Trials Information System (CTIS)**  
Nil known

**ClinicalTrials.gov (NCT)**  
Nil known

**Protocol serial number**  
2019-02-25

## Study information

**Scientific Title**  
Efficacy of Qingrehuashiquyu recipe on ulcerative colitis: a randomized controlled study

**Study objectives**

Combination of Qingrehuashiquyu recipe and mesalazine is more effective in the treatment of ulcerative colitis than mesalazine used alone.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Approved 25/02/2019, Ethics Committee of Beijing Chinese Medicine Hospital affiliated to Capital Medical University (Beijing Hospital of Traditional Chinese Medicine Capital Medical University No. 23 Art Museum Houjie Street Dongcheng District; ecbjtcmm@126.com; +8601052171516), ref: 2019BL02-007-01

### **Study design**

Interventional single-center randomised controlled trial

### **Primary study design**

Interventional

### **Study type(s)**

Treatment

### **Health condition(s) or problem(s) studied**

Ulcerative colitis

### **Interventions**

Participants are randomly allocated to one of two groups using SAS9.10 software:

1. Qingrehuashiquyu recipe 200ml, taken orally two times per day and mesalazine 0.25gtaken orally four times per day for 12 weeks
2. Mesalazine 0.25gtaken orally four times per day for 12 weeks

Following completion of this 12 week period, there is another 12 week follow-up period.

Clinical symptoms data and samples including blood, stool and colonic mucosa will be collected by clinicians. Blood will be collected by drawing blood of centrifugal vein. Stool will be collected by specimen box. Colonic mucosa will be collected by electronic endoscope.

### **Intervention Type**

Drug

### **Phase**

Not Specified

### **Drug/device/biological/vaccine name(s)**

Qingrehuashi quyu recipe

### **Primary outcome(s)**

Current primary outcome measure as of 29/10/2021:

Mayo Activity Index, assessed at baseline and 12 weeks

Previous primary outcome measure:

Mucosal histology score measured using Geboes index, assessed at baseline and 12 weeks.

## **Key secondary outcome(s)**

Current secondary outcome measures as of 29/10/2021:

1. Mucosal histology score measured using Geboes index, assessed at baseline and 12 weeks
2. Traditional Chinese Medicine syndromes of UC score, assessed at baseline,4,8 and 12weeks
3. Fecal occult blood test, erythrocyte sedimentation rate, C-reactive protein, fecal calprotectin at baseline and 12weeks
4. Detection of intestinal apoptosis at baseline and 12 weeks
5. Detection of intestinal flora at baseline and 12 weeks
6. Detection of intestinal nitric oxide at baseline and 12 weeks
7. Inflammatory bowel disease quality of life scale at baseline and 12 weeks

Previous secondary outcome measures:

1. Mayo Activity Index, assessed at baseline and 12 weeks
2. Traditional Chinese Medicine syndromes of UC score, assessed at baseline,4,8 and 12weeks
3. Fecal occult blood test, erythrocyte sedimentation rate, C-reactive protein, fecal calprotectin at baseline and 12weeks
4. Detection of intestinal apoptosis at baseline and 12 weeks
5. Detection of intestinal flora at baseline and 12 weeks
6. Detection of intestinal nitric oxide at baseline and 12 weeks
7. Inflammatory bowel disease quality of life scale at baseline and 12 weeks

## **Completion date**

01/08/2022

## **Eligibility**

### **Key inclusion criteria**

1. The diagnosis of ulcerative colitis is active, and the clinical severity is mild to moderate.
2. Meeting the Traditional Chinese Medicine syndrome of large intestinal damp-heat criteria.
3. The age is between 18 and 65 years old, and gender is not limited.
4. The patient signs informed consent. The process of obtaining informed consent should be in accordance with GCP regulations.

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

### **Age group**

Adult

### **Lower age limit**

18 years

### **Sex**

All

### **Key exclusion criteria**

1. The type of ulcerative colitis is acute fulminant, and the severity of the condition is severe.
2. Infectious colitis such as bacillary dysentery, amoebic sputum, chronic schistosomiasis, intestinal tuberculosis, and patients with Crohn's colitis, ischemic enteritis, and radiation enteritis.
3. Patients with serious complications such as local stenosis, intestinal obstruction, intestinal perforation, rectal polyps, toxic colonic dilatation, colon cancer, rectal cancer and anal disease.
4. Pregnant and lactating women
5. Those with severe primary heart, liver, lung, kidney, blood or serious diseases that affect their survival.
6. Disabled patients prescribed by law.
7. Suspected or indeed had a history of alcohol and drug abuse.
8. Poor compliance or any other reason the researchers believe may not be appropriate to participate in this trial.
9. Allergic constitution or known to be allergic to the drug used in this trial.
10. Patients who are participating in other drug clinical trials.

**Date of first enrolment**

20/04/2019

**Date of final enrolment**

01/05/2021

## Locations

**Countries of recruitment**

China

**Study participating centre****Digestive Disease Center**

Beijing Hospital of Traditional Chinese Medicine

Capital Medical University

No. 23

Art Museum Houjie Street

Dongcheng District

Beijing

China

100010

## Sponsor information

**Organisation**

Beijing Municipal Science & Technology Commission

**ROR**

<https://ror.org/034k14f91>

# Funder(s)

## Funder type

Government

## Funder Name

Beijing Municipal Science and Technology Commission

## Alternative Name(s)

Science and Technology Commission of Beijing Municipality, Beijing Municipal Science & Technology Commission, Administrative Commission of Zhongguancun Science Park, Beijing Municipal Science and Technology Commission, Beijing Municipal Science & Technology Commission, , ,

## Funding Body Type

Government organisation

## Funding Body Subtype

Local government

## Location

China

# Results and Publications

## Individual participant data (IPD) sharing plan

The current data sharing plans for this study are unknown and will be available at a later date.

## IPD sharing plan summary

Data sharing statement to be made available at a later date